Primary biliary cirrhosis and bile acids.

Area of Science:

• Hepatology
• Immunology
• Pharmacology

Background:

• Primary biliary cirrhosis (PBC) is a chronic cholestatic autoimmune disease causing bile duct destruction and liver fibrosis.
• Ursodeoxycholic acid (UDCA) has been the standard treatment for 20 years, acting as a hydrophilic bile acid with secretagogue, anti-inflammatory, and anti-apoptotic properties.

Purpose of the Study:

• To review the current understanding of UDCA's efficacy and explore novel therapeutic targets for PBC.
• To evaluate emerging treatments targeting nuclear and membrane receptors involved in bile acid homeostasis.

Main Methods:

• Review of existing literature on UDCA treatment in PBC.
• Analysis of recent experimental and Phase II clinical trial data for novel agents.
• Focus on nuclear receptors (FXR, PXR, PPARα) and membrane receptor TGR5.

Main Results:

• UDCA demonstrates benefits beyond its hydrophilic nature, including secretagogue and anti-inflammatory effects.
• Combined therapy with budesonide shows additional benefits in PBC.
• Emerging FXR and PPARα agonists (obeticholic acid, bezafibrate, fenofibrate) show promise as add-on or alternative first-line therapies.

Conclusions:

• Significant progress in understanding bile acid homeostasis has identified new therapeutic targets for PBC.
• Novel agents targeting FXR and PPARα represent a potential new era in PBC treatment, offering alternatives for non-responsive patients.